Podcasts about Icis

Join Mark Victory, Senior Editor, Recycling at ICIS as he asks Valentijn De Neve, CEO of BlueAlp and president of industry association Chemical Recycling Europe, and Egor Dementev, ICIS EMEA recycling analytics team lead about mass balance accounting and the future of the chemical recycling industry following the publishing of the  Single Use Plastic Directive implementing act.Key topics covered include: Mass balance accounting rules and how the final version differs from the draft SUPD implementing act The role of competition with other circular plastic routes and how it might shape chemical recycling's future What success looks like for chemical recycling in 2026 ICIS assesses more than 100 grades throughout the circular plastic value chain globally – from waste bales through to pellets. This includes recycled polyethylene (R-PE), recycled PET (R-PET), R-PP, mixed plastic waste, agglomerates, pyrolysis oil and bio-naphtha.  For more information on ICIS' recycled plastic products, please contact the ICIS recycling team at recycling@icis.com

The UK chemical industry needs more swift and powerful regulatory support to save it from further erosion as production falls by more than half compared to 2021 levels. -          25 UK chemicals closures since 2021, country now only has one cracker-          Massive social impact of closures, often in deprived areas-          UK no longer produces some critical chemicals-          Lost UK chemical production could reach 55-60% from 2021 levels-          UK needs much more powerful government policy shift to save industry-          UK chemicals sees toughest business environment for many years-          Slight pick up expected in 2026-          For 2026, chemicals output forecast to contract in US, tepid growth in Europe, China-          India forecast 7% in chemicals output for 2026-          More protection needed against China, which has moved up the chemicals value chain and subsidises productionIn this ICIS Think Tank podcast, Will Beacham interviews Stephen Elliott, CEO of the UK Chemical Industries Association and ICIS market development director John Richardson.

In this episode, Dr. Madeline O'Sullivan discusses her retrospective study of U.S. veterans in the Veterans Health Administration, examining outcomes among patients with rheumatoid arthritis treated with immune checkpoint inhibitors for cancer. She explains how the cohorts were defined, how use and timing of immunosuppressive therapies were analyzed, and how mortality and cause of death were determined. Dr. O'Sullivan summarizes the patient population, cancer types represented, and key findings on survival differences between RA and non-RA groups, as well as insights from secondary analyses and important study limitations. She also reflects on balancing research with clinical training, the mentorship that supported her work, lessons learned, and practical advice for trainees aiming to complete and publish research projects. 

Join Egor Dementev, ICIS EMEA recycling analytics team lead, as he asks Valentijn De Neve, CEO of BlueAlp and President of industry association Chemical Recycling Europe, and ICIS senior editor recycling Mark Victory about Chemical recycling regulation following the passing of the implementing act on mass balance accounting under the Single Use Plastic Directive, and the future of the industry.   The Single Use Plastic Directive (SUPD) implementing act which sets out the mass balance approach for chemically recycled PET End of Waste Status for pyrolysis oil and the Winter Package The need for investment in chemical recycling regardless of regulatory clarity The volume of recycled material needed for food-contact applications by 2030 and 2040 Chemical recycling demand through to 2030

Les niveaux des stocks européens de gaz sont tombés à environ 37%, soit en-dessous de la moyenne de ces cinq dernières années, et ont provoqué une forte hausse des prix au mois de janvier 2026. Une hausse qui s'est depuis atténuée. Les stocks sont tombés si bas car les Européens sont entrés dans l'hiver avec des réserves inférieures à celles des années précédentes, explique Greg Molnar, analyste gaz de l'Agence internationale de l'énergie (AIE), c'est-à-dire avec des infrastructures remplies à peine au-dessus de 80% de leur capacité. À ce « mauvais départ » est venue s'ajouter une vague de froid début janvier qui a fait augmenter la demande et fait baisser les stocks. Si la consommation continue au rythme habituel, l'Union européenne pourrait terminer l'hiver avec seulement 25% de ses capacités remplies, soit le niveau le plus bas depuis la saison hivernale 2017-2018.  Des importations record en 2026 ? La diminution des stocks annonce des importations plus importantes cette année. L'AIE s'attend même à une hausse record des achats en 2026. Il n'y a pas d'inquiétude à avoir du côté de l'offre, car la production de gaz naturel liquéfié (GNL) devrait être en augmentation cette année – estimée à 472 millions de tonnes sur l'ensemble de l'année par le cabinet d'étude ICIS. Plusieurs pays vont voir en effet croître leurs capacités d'exportation grâce à l'agrandissement de leurs infrastructures ou la mise en service de nouveaux projets. On peut citer le Canada, les États-Unis, le Mexique, le Congo-Brazzaville – le fournisseur italien ENI a chargé, le 7 février, la première cargaison de son unité flottante Nguya – ou encore l'Australie.  D'autres projets sont annoncés d'ici 2027, au Qatar notamment, et devraient continuer à faire grimper les quantités de GNL disponibles dans le monde. Cette montée en puissance de la production évitera peut-être la hausse des prix que certains craignent, au vu de la forte demande européenne qui se profile cet été.  L'Europe, partenaire privilégié des États-Unis L'Europe a un partenaire privilégié : les États-Unis. En janvier, le pays a fourni 60% des importations européennes, contre 53% en janvier 2025, et 24% début 2021 selon l'agence Reuters. Ce chiffre augmente depuis plusieurs années et a été consolidé par un accord commercial entre l'Europe et Donald Trump. Mais le poids grandissant pris par les États-Unis fait courir un risque à l'Europe, a fait récemment remarquer le commissaire européen à l'Énergie, Dan Jorgensen, après les menaces du président états-unien sur le Groenland : celui de remplacer la dépendance au gaz russe par une dépendance au gaz américain. Des discussions sont donc en cours, selon le commissaire européen, avec le Canada, le Qatar et l'Afrique du Nord pour sécuriser d'autres canaux d'approvisionnement. C'est dans cet objectif de diversification que l'énergéticien allemand RWE a signé, le 6 février, un accord commercial avec les Émirats arabes unis.

Is China's polyethylene market heading for a crash or a recovery? In the latest ICIS podcast, senior industry analyst Joanne Wang sits down with Amy Yu ,  Asian PE lead from Analytical team to dive into the "tug-of-war" defining 2026. Together, they break down how the 6.2 million-tonne capacity surge is clashing with sudden price shocks caused by Middle East tensions.

In this podcast, experts Drs. Hope Rugo, Alison Conlin, Marleen Kok and Heather McArthur discuss results of recent pivotal clinical trials and their impact on current and evolving treatment paradigms for patients with metastatic triple-negative breast cancer.

On January 20th, Women in Chemicals started off the new year with a chemical markets outlook! Watch this recorded presentation on the current state of the chemical industry from the team at ICIS (Independent Commodity Intelligence Services), State of the Industry with ICIS, to get insights on the economic forecasts, supply chain challenges, and sustainability trends that will define the chemical industry in 2026.

Lithuania's offshore Klaipeda LNG terminal had a record year in 2025, with the port's utilisation rate soaring well above the EU average. Operator KN Energies anticipates an even better year in 2026. It has launched an open season for long-term capacity and is expecting more central and eastern European companies to use its services as they are looking for a diversity of sources and routes. Although traders are incentivised by Klaipeda's ease of doing business and transparency, they also flag limitations related to regional market liquidity and high regional transmission tariffs. In this interview, Darius Silenskis, CEO of KN Energies, tells ICIS reporter Aura Sabadus about the company's short and long-term plans and its role in supporting market liquidity. 

The EU's biomethane market has been developing at speed.Since 2023, production has risen more than 30% and the fuel is fast becoming not just an instrument to reach energy transition targets but is also making a real contribution to security of supply.A number of western European countries including France, Germany, Denmark, Italy, the UK are leading the way thanks to their extensive agricultural sectors and well designed subsidies schemes.However, building a single pan-European market is still a distant dream.ICIS energy news editor Andrea Battaglia tells senior reporter Aura Sabadus about the merits of this emerging sector but also the challenges that are slowing down progress.

Despite widespread geopolitical instability around the world, the most severe period of crude oil oversupply ever will depress prices, latest ICIS forecasts show.   -          For 2026 global oil markets are in the largest period of oversupply we have ever seen-          Oversupply forecast by ICIS at 3 million barrels/day out of a roughly 100 million barrels/day market-          China oil demand growth has slowed drastically thanks to slowing economy and transition to electric vehicles-          OPEC is increasing supply, unwinding previous cuts-          Around 20% of global oil supplies pass through Strait of Hormuz so closing it could push prices above $100/barrel. -          End Q1/early Q2 Brent crude oil prices could decline under $60/barrel as fundamentals of oversupply take over from geopolitical concerns-          Overall prices could be 15% lower than in 2025, ICIS forecasts-          China-driven chemicals oversupply will persist in 2026-          Developing world outside China may become a driver of chemicals demand-          SABIC's petrochemical sale ushers in new era of ownership by turnaround investors In this Think Tank podcast, Will Beacham interviews ICIS market development director John Richardson, ICIS Insight Editor Tom Brown and Ajay Parmar, head of oil markets for ICIS.  

Greenland has been holding the headlines in recent weeks as US President Donald Trump expressed an open interest in acquiring the world's largest island amid claims of security risks in the Arctic region.Many observers reject the argument, insisting the race to take over the resource-rich island and possibly even neighboring Canada is largely driven by economic considerations.Canada and Greenland already have long-standing security arrangements with the US and extracting more fossil fuels at a time when the world is already awash with oil and gas does not make sense.What, then, is driving the latest US policy in the Arctic region?ICIS senior journalist Aura Sabadus has invited Arctic expert Dr Petra Dolata, associate professor at the University of Calgary, Canada, to find out.

The US military operation in Venezuela at the start of 2026 resulting in the capture of president Nicolas Maduro had a modest immediate impact on oil prices. However, questions raised by these events are highly consequential for global markets and the future geopolitical power balance.Shares in some US-listed oil companies rose sharply after the operation, but who will be the real winners and losers in the long term? What are the implications for global oil and gas markets, amid protests rocking Iran and the possibility other resource-rich countries and territories such as Canada, Colombia, Greenland or Mexico could be on Washington's target list? Senior reporter Aura Sabadus has invited ICIS global crude oil editor Barney Gray and senior oil analyst David Jorbenaze to reflect on latest developments and the long-term outlook for markets.  

With the prospect of global overcapacity easing from around 2030, Middle East petrochemical players are debating how to monetise their plentiful natural gas supplies.  Middle East producers plan a major new capacity wave after 2030,  Long‑term strategy centres on monetising hydrocarbons beyond 2030 China's overcapacity cycle may ease by around 2030,  Debate about staying focused on simple, large‑volume commodity grades or moves into higher‑value or specialty polymers Climate‑driven demographic and economic pressures in the Global South could reshape demand Chinese competition in high‑value chemicals is intensifying Maintaining strong ties with China remains important today Massive crude oil‑to‑chemicals (COTC) ambitions are being moderated Partnerships and M&A are key tools for Middle East companies to secure technology, expand globally, and balance portfolios   In this Think Tank podcast, Will Beacham interviews ICIS senior consultant John Richardson. Download a special issue of ICIS Chemical Business with full coverage of the recent Gulf Petrochemical Association (GPCA) event. 

The loss of Russian gas imports, associated long-term capacity bookings and the reversal of gas flows in central and eastern Europe have led to soaring transmission tariffs and inevitably heated debates.  After decades of operating on a fairly simple business model, gas grid operators, regulators, traders and consumers are faced with multiple dilemmas on how to minimise costs while also ensuring revenue to meet challenges.  A patchwork of different views and approaches has emerged, often to the detriment of consumers, raising questions whether the EU's network codes still provide the answer to managing complex situations. In this interview, Walter Boltz, former head of Austrian regulator E-Control, tells ICIS senior reporter Aura Sabadus that an altogether new vision is required that will require the involvement of the European Commission, ACER and ENTSOG.  

Delving into the latest JAHA review on immune checkpoint inhibitors and the heart has been illuminating

China has a huge impact on the global chemical industry in terms of supply and demand so analysis of future demographic and economic trends is important for business leaders. -          Huge variation in forecasts for changes in population-          Chemicals demand growth scenario planning is vital-          Must take into account China's success in technology and exports-          Demand boost if export earnings are funnelled back into pension and healthcare reforms-          ICIS base case 2025-2050 sees 2% polyolefins demand growth per annum, down from  10% between 1992 and 2024-          More container traffic may return to the Suez Canal if ceasefire holds

The EU's Carbon Border Adjustment Mechanism (CBAM) will be moving up a gear from 2026 when EU importers are expected to purchase and surrender CBAM certificates to cover the embedded emissions of imported carbon-intensive goods.Regulations will impact Energy Community contracting parties such as Ukraine, Moldova, Georgia and the West Balkans countries either through their exports of electricity or other energy-intensive products. ICIS journalist Aura Sabadus has spoken to Peter Pozsgai, lead of the CBAM Readiness Task Force at the Energy Community, to understand the exact implications for both EU importers and Energy Community contracting parties.  

Transmission capacity on the Romanian-Moldovan border was overbid at quarterly auctions held in November as traders have been competing to sell gas to Moldova this winter. Only five years ago such a scenario would have been unthinkable. The country was fully reliant on Russian gas and depended heavily on Russian-controlled Transnistria for electricity supplies. After multiple energy crises triggered by Russia since then, Moldova has fast-tracked the implementation of EU-aligned reforms. Within less than six months it will start its gradual liberalisation of the gas sector and by 2027 it expects to couple its electricity spot market with that of the EU. However, as Constantin Borosan, director of energy regulator ANRE tells ICIS journalist Aura Sabadus, there are still many challenges ahead. These include ensuring the correct framework for functional power and gas markets, expanding the border gas capacity with Romania and Ukraine to facilitate regional transit and thinking long-term about the future of Transnistria's energy arrangements.    

In this episode of Product & Packaging Powerhouse, host Megan Young Gamble recaps her experience at Makeup in New York 2025, from day 1 and this episode focusing on day two themes of packaging innovation, sustainability, and beauty tech. She shares actionable insights from industry panels including advances in sustainable packaging (like APC Packaging's patented mono-material droppers and refillable solutions), compliance considerations, smart packaging, and the importance of consumer psychology. Startup brand Rebel Queen's all-in-one curly hair product is highlighted for its minimalistic approach, while expert Roberta Sironi provides a masterclass on mascara packaging, launching an academy for deeper industry education. Megan ties it all together with observations on tech (especially AI's growing role in beauty and packaging), and offers advice for brands considering trade shows, encouraging startups to attend for valuable connections and inspiration. Be sure to check out Day 1 Recap HERE. Access our other podcast episodes mentioned during the episodeInside MakeUp in New York: Day 1 Innovation and Tech” with Megan Young Gamble. Listen HerePackaging Design, Influence, & Integrity" with Vicki Strull, Founder, Vicki Strull Design. Listen HereThe Truth About Stress, Skincare, and Your Immune System” with Dr. Ebru Karpuzoglu, Immunologist and founder of AveSeena and ChicScience Labs. Listen HereRoundtable: Packaging, Plastics & Platforms toward Circular Economy” with Emily Anne Friedman (Recycled Plastics Editor, ICIS), Ryan Fox (Packaging Analyst, Bloomberg Intelligence) and Nicole Toole (Founder of ECGO.) Listen HereHow Connected Packaging Shapes Sustainability and Traceability” with John Dwyer, Smart Packaging Expert at Smurfit Westrock & Maurizio Carano, Innovation & Marketing Director IML @ MCC Label. Listen HereAffiliate & Other Links: [Megan Young Gamble Links][AFFILIATE] Ready to crank out your content in as little as 5 minutes? Use Castmagic, AI powered tool to take your content creation from overwhelmed to overjoyed by saving hours of developing content. Save 20 hours by Signing up today! https://get.castmagic.io/Megan [FREEBIE] Learn about “day in the life” of a Packaging Project Manager → Get our “Starter Packaging PM Freebie” [link] https://glc.ck.page/thestarterpackagingprojectmanager [FREEBIE] Access commonly referenced organizations and tools in ONE PLACE with our handy guide HERE [link] https://bit.ly/OSTPlay Subscribe & Access our Video Vault YouTube Channel [ link] https://bit.ly/GLConYouTubeJoin our Email List [link] https://glc.ck.page/55128ae04b Follow and Connect with Megan on LinkedIn [link] https://linkedin.com/in/megangambleLearn about GLC, Packaging & Project execution firm for CPG brands http://www.getlevelconsulting.comWork with Me @ GLC, Schedule Discovery Call https://calendly.com/getlevelconsulting/15-minute-insight-sessionGot a topic you'd love us to cover? Share your ideas here [link] https://bit.ly/ppptopicformContact details of Jennifer Lehto, Senior Business Development Manager at APC PackagingLinkedin - https://www.linkedin.com/in/jenniferlehtoEmail id - jenniserl@apcpackaging.comRoberta Sironi, Chief Commercial Officer at Pibiplast SpaLinkedin - https://www.linkedin.com/in/roberta-sironi-0636982/Pibiplast academy - https://pibiplast.com/certificationsQuotes and Hooks:  We've always been very conscious about our scalp health because you have to make sure your scalp is clean to help with promoting hair growth.Smart packaging gives each product their own digital passport telling consumers what it is, where it came from and what to do at the end of life.Everybody wants sustainable packaging, but the real question is: what does sustainability mean to you and your brand?Glass is heavier, costs more to ship, and is prone to breakage, so is it really deemed sustainable? Something to think about.I struggled for years to find the perfect curly hair product and I finally created it, an all-in-one that hydrates, defines, and controls frizz. (Bleema, Rebel Queen)Mascara is a really complex product, you need a lot of technicity to make the magic and make the product work. (Roberta Cerroni, Pibi Plast)AI is here to stay, and I use ChatGPT as my daily assistant all the time to help me think through things and shorten cycle times.Would I attend Makeup In New York again? Absolutely. Is it a trade show that I would recommend any company to attend? Absolutely.

In this episode, we talk with Dr. Sharon about the complex intersection of oncology and autoimmunity through the lens of immune checkpoint inhibitors (ICIs)—therapies that have transformed cancer care but can also unleash immune-related adverse events (irAEs). Dr. Elad explains how ICIs work, why they can trigger autoimmune-like toxicities, and what distinguishes rheumatologic irAEs from classic autoimmune diseases. We explore the mechanistic overlaps between cancer immunotherapy and autoimmunity, the ethical and clinical dilemmas of balancing immune suppression with cancer control, and emerging biomarkers that may predict risk. Dr. Sharon also reflects on his career journey—from leading drug development efforts at the National Cancer Institute to returning to academia—and shares insights on collaboration, innovation, and the evolving partnership between oncologists and rheumatologists in managing these challenging conditions. 

Maintenance therapy with ICIs (atezolizumab or durvalumab) is already established in extensive stage small-cell lung cancer, but lurbinectedin enters the chat with a recent FDA approval. Next up - tarlatamab? IMforte (maintenance lurbinectedin + atezolizumab): https://doi.org/10.1016/S0140-6736(25)01011-6 DeLLphi-303 (phase 1b maintenance tarlatamab + ICI): https://doi.org/10.1016/S1470-2045(25)00480-2

In this JCO Precision Oncology Article Insights episode, Dr. Jiasen He summarizes JCO PO article "Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer" by Hua Zhong et al. TRANSCRIPT Jiasen He: Hello and welcome to the JCO Precision Oncology Article Insights. I am your host, Jiasen He, and today we will be discussing the JCO Precision Oncology article, "Synthetic Lethal Co-mutations in DNA Damage Response Pathway Predict Response to Immunotherapy in Pan-Cancer" by Dr. Zhang and colleagues. Immunotherapy has emerged as a groundbreaking treatment option for many types of cancer. However, the overall response rate to immunotherapy is low, around 10% to 30%. This highlights the critical need to identify which patients are most likely to benefit from immunotherapy. Two of the most extensively studied biomarkers are PD-L1 expression and tumor mutation burden (TMB). High levels of PD-L1 and TMB have been associated with better response to immune checkpoint inhibitors, which are now widely used in clinical practice. The predictive value of these markers is inconsistent across all settings. Some tumors with high PD-L1 or TMB still respond poorly to immunotherapy. One reason is that TMB reflects new antigen production, but recent studies suggest that new antigen levels do not always correlate with tumor immunogenicity. Many new antigens are not effectively recognized by T cells, limiting the immune response. Emerging evidence indicates that mutations in the DNA damage response (DDR) pathway play a critical role in moderating tumor immune interactions. Tumors harboring DDR pathways frequently exhibit increased genome instability, which may enhance their sensitivity to immune checkpoint inhibitors. While all these pathways are under active investigation, the optimal DDR pathway biomarkers for patient selection remain unclear. Notably, tumor cells with a defect in one DDR pathway may acquire greater reliance on alternative DDR pathways. Recent studies suggest that synthetic lethal co-mutations within DDR pathways are associated with immune-inflamed or hot tumor microenvironments. Based on this rationale, Dr. Zhang is investigating if synthetic lethal co-mutations in DDR pathway response pathway can serve as a treatment biomarker for immune checkpoint inhibitors. To address this question, Dr. Zhang and colleagues first utilized SynLethDB 2.0, a comprehensive database that integrated multiple data sets. Synthetic lethal (SL) gene pairs in this resource are identified through both experimental and computational approaches, with confidence scores assigned to each pair. These SL pairs were then mapped to gene sequencing results from several clinical cohorts. SL co-mutation status was defined as positive when both genes in a synthetic lethal pair were mutated. From this, SL co-mutation pairs specifically involving DDR pathway genes were selected. Patients were classified as DDR co-mutation positive if both genes in a synthetic lethal pair, each belonging to the defined DDR pathways, were mutated. In total, 431 DDR-related SL pairs were identified and matched to sequencing data from clinical cohorts. Clinical information was extracted from the cBioPortal, while further analysis of immune infiltration was performed using DNA mutation and RNA expression data from The Cancer Genome Atlas (TCGA) pan-cancer data set. The author first examined the correlation between SL co-mutation status and response to ICI therapy. They discovered that patients with SL co-mutation showed significantly improved outcome to ICI therapy across various clinical cohorts. Notably, in patients who did not receive ICI treatment, patients with SL co-mutation showed markedly compromised overall survival. Further analysis focused on the predictive value of SL co-mutation within DDR pathway genes. The author found that patients with DDR SL co-mutation had a longer overall survival compared to those with mutations in a single DDR gene, implying that SL co-mutations may be more effective biomarkers within the DDR pathway. To explore this further, in the TMB-MSKCC cohort, the author found that patients with DDR co-mutation constituted approximately 20% of various cancer types, including non-small cell lung cancer, melanoma, and bladder cancer. These patients demonstrated significantly better survival outcomes and disease control rates when treated with ICIs compared to DDR co-mutation negative patients. Notably, the TMB level was substantially higher in patients with DDR co-mutation, a finding consistent with data from the Miao-lung cohort. Furthermore, in cohorts not treated with ICIs, patients with DDR co-mutation had a shorter overall survival compared to their counterparts. Upon stratifying by PD-L1 expression, the author observed that patients with DDR co-mutation who were also PD-L1 positive derived the greatest clinical benefit from ICI therapy. Upon analyzing the frequency of co-mutation within the DDR pathway, the authors found that patients with SL co-mutation in the CPF-CPF pathway experienced remarkable survival benefit from ICIs. Within this group, one of the most common co-mutation combinations was TP53-ATM, observed in approximately 45% of cases, which was associated with a better response to ICI therapy. Further analysis of immune cell infiltration revealed that patients with TP53-ATM co-mutation exhibited a distinct tumor immune microenvironment. As the authors stated, the study's main limitation lies in the nature of retrospective analysis, which lacked the control over confounding variables and was subject to non-random sampling. For instance, patients with both SL co-mutations and DDR SL co-mutations exhibited high TMB, and TMB was known to be associated with improved response to ICI therapy itself. So, these findings require validation through prospective studies, and immune infiltration analysis needs confirmation via laboratory experiments. In conclusion, the authors found that patients with SL co-mutations in DDR pathways showed favorable clinical response and prolonged survival following ICI therapy. They also identified TP53-ATM co-mutations as a clinically relevant biomarker for predicting ICI treatment response. Thank you for tuning in to JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

In this special roundtable episode of the Product and Packaging Powerhouse, host Megan Young Gamble sat down with industry experts Emily Anne Friedman (Recycled Plastics Editor, ICIS), and Ryan Fox (Packaging Analyst, Bloomberg Intelligence) and Nicole Toole (Founder of ECGO) to unpack definitions of sustainability, the impact of data and technology, consumer education, and policy approaches like EPR. The panel considers how to move toward a more circular economy, while acknowledging the real-world constraints of infrastructure, cost, and market incentives.Affiliate & Other Links: [Megan Young Gamble Links][AFFILIATE] Ready to crank out your content in as little as 5 minutes? Use Castmagic, AI powered tool to take your content creation from overwhelmed to overjoyed by saving hours of developing content. Save 20 hours by Signing up today! https://get.castmagic.io/Megan [FREEBIE] Learn about “day in the life” of a Packaging Project Manager → Get our “Starter Packaging PM Freebie” [link] https://glc.ck.page/thestarterpackagingprojectmanager [FREEBIE] Access commonly referenced organizations and tools in ONE PLACE with our handy guide HERE [link] https://bit.ly/OSTPlay Subscribe & Access our Video Vault YouTube Channel [ link] https://bit.ly/GLConYouTubeJoin our Email List [link] https://glc.ck.page/55128ae04b Follow and Connect with Megan on LinkedIn [link] https://linkedin.com/in/megangambleLearn about GLC, Packaging & Project execution firm for CPG brands http://www.getlevelconsulting.comWork with Me @ GLC, Schedule Discovery Call https://calendly.com/getlevelconsulting/15-minute-insight-sessionGot a topic you'd love us to cover? Share your ideas here [link] https://bit.ly/ppptopicform [Powerhouse Guests Social Links]  1. Emily Anne Friedman - Recycled Plastics Senior Market Editor, Americas ICISLinkedIn: https://www.linkedin.com/in/emilyannefriedman/Company Website: https://www.icis.com/explore/2. Nicole Toole - Founder & CEO at ECGOLinkedIn: https://www.linkedin.com/in/nicole-toole/Company website: https://www.ecgo.co/3. Ryan Fox - Corrugated Packaging Market Analyst at Bloomberg Intelligence Linkedin : https://www.linkedin.com/in/ryandfox/Company website: https://www.green-markets.com/BOX/Index.htmlAdditional Resource: Pizza box recycling - https://www.westrock.com/blog/pizza-box-recycling Here's a great resource to help understand curbside recycling trends. - https://recyclingpartnership.org/residential-recycling-report/ [Podcast] Be a Packaging Steward": Packaging Sustainability, Sales and Intentional Connections with Adam Peek “Packaging Pastor” SVP of Meyers | Host of People of Packaging Podcast. Listen here[Podcast] How Connected Packaging Shapes Sustainability and Traceability” with John Dwyer, Smart Packaging Expert at Smurfit Westrock & Maurizio Carano, Innovation & Marketing Director IML @ MCC Label. Listen hereEpisode Quotes:.It's one thing to give someone a recycling bin, it's another thing for them to actually treat it like one. - EmilyYour PCR, which is post-consumer recycled content, is very important, but you also have to ask, where is that recycled material coming from and what's the overall carbon footprint? - EmilyUltimately when we think about shifting people's behavior, it's adopting the values of waste stewardship and ensuring products have the best end-of-life process. - NicoleThe biggest barriers are incentives and confusion, so we built technology to make it easy, local, and rewarding. - NicoleEvery year, corrugated captures about 35 million tons of old containers and turns them into a brand-new version that circularity is sustainability. - RyanOne of the challenges is inspiring people at home to take a bigger role in recycling. That's where the biggest difference will come. - RyanSometimes the greenest thing from a greenhouse gas perspective is actually plastic, but it's the one that gets hit the hardest. - Ryan

In this podcast, experts Virginia Kaklamani, MD, DSc, and Tiffany A. Traina, MD, FASCO, discuss the rationale for and data to support combining TROP2-targeting antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) to treat triple-negative breast cancer (TNBC).

Нещодавні удари України по трубопроводу «Дружба» — це не тільки атака на військову економіку Росії. Це також тривожний сигнал для угорцівАвтор: Ора Сабадус, старший журналіст із енергетичних питань Незалежної Комерційної Служби розслідувань (ICIS), кандидат наукНачитала: Наталія Чекаль 

CME credits: 0.25 Valid until: 29-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/global-perspectives-on-perioperative-immunotherapy-in-la-hnscc/36261/ Join our experts as they examine the integration of perioperative immune checkpoint inhibitors (ICIs) in the management of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). Drs. Le Tourneau and Harrington discuss unmet needs and limitations of current treatment and review data from trials supporting the use of perioperative ICIs, emphasizing their event-free survival and pathologic response outcomes. The conversation also addresses multidisciplinary coordination and considerations for managing immune-related adverse events. Variations in treatment guidelines, access, and clinical practice between the US, Europe, and other regions are explored to contextualize the challenges of global implementation and provide strategies for practitioners to improve care. =

CME credits: 0.25 Valid until: 29-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/global-perspectives-on-perioperative-immunotherapy-in-la-hnscc/36261/ Join our experts as they examine the integration of perioperative immune checkpoint inhibitors (ICIs) in the management of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). Drs. Le Tourneau and Harrington discuss unmet needs and limitations of current treatment and review data from trials supporting the use of perioperative ICIs, emphasizing their event-free survival and pathologic response outcomes. The conversation also addresses multidisciplinary coordination and considerations for managing immune-related adverse events. Variations in treatment guidelines, access, and clinical practice between the US, Europe, and other regions are explored to contextualize the challenges of global implementation and provide strategies for practitioners to improve care. =

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-collaboration-facilitates-multimodality-therapy/36636/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/rationale-for-combining-radiation-and-immunotherapy-in-resectable-locally-advanced-hnscc/36592/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-in-the-perioperative-setting/36635/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/applying-perioperative-icis-in-clinical-practice/36634/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-landscape-of-resectable-locally-advanced-hnscc/36576/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/rationale-for-combining-radiation-and-immunotherapy-in-resectable-locally-advanced-hnscc/36592/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/applying-perioperative-icis-in-clinical-practice/36634/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-for-perioperative-icis-in-locally-advanced-hnscc/36593/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-in-the-perioperative-setting/36635/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-collaboration-facilitates-multimodality-therapy/36636/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-landscape-of-resectable-locally-advanced-hnscc/36576/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-for-perioperative-icis-in-locally-advanced-hnscc/36593/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

CME credits: 0.75 Valid until: 22-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/ This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

This week on The OncoAlert Weekly Round Up, we spotlight precision oncology in action with top-tier studies making headlines:

BUFFALO, NY – June 20, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 10, 2025, titled “Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors.” In this paper, led by first author Helen Qian and corresponding author Crismita Dmello from Northwestern University Feinberg School of Medicine, researchers compiled growing evidence that the CHEK2 gene, long known for its role in repairing DNA damage, may also influence how tumors respond to immunotherapy. Their analysis suggests that problems in CHEK2 function might make cancer cells more vulnerable to immune system attacks, highlighting a new opportunity to improve treatment outcomes in solid tumors. Immune checkpoint inhibitors (ICIs) have transformed cancer treatment; however, they are effective in only a subset of patients. This review suggests that tumors with reduced CHEK2 activity may accumulate more mutations that produce signals the immune system can recognize. These signals, known as neoantigens, help immune cells identify and destroy cancer cells more effectively. The review connects this process not only to CHEK2's established role in the DNA damage response but also to a newly proposed function in shaping the immune environment of tumors. CHEK2 normally helps maintain genomic stability by enabling precise DNA repair. When this function is lost, cells rely on more error-prone repair methods, leading to additional mutations. These mutations can increase tumor mutational burden, which has been linked to better outcomes with immunotherapy. Beyond DNA repair, the review highlights a second mechanism: activation of the cGAS-STING pathway. This pathway detects fragments of damaged DNA and triggers inflammation that attracts immune cells to the tumor. The authors highlight studies where CHEK2-deficient tumors responded better to PD-1 inhibitors, a common type of immune checkpoint inhibitor. In both lab models and early-stage clinical settings, CHEK2 loss was associated with increased infiltration of CD8+ T cells—immune cells essential for attacking cancer cells. In cancers such as glioblastoma and renal cell carcinoma, which are typically resistant to immunotherapy, reduced CHEK2 expression was linked with more favorable immune activity and higher expression of interferon-related genes. The compiled evidence points to CHEK2 as a potential biomarker for identifying patients likely to respond to immunotherapy. In addition, combining CHEK2 inhibitors with existing immunotherapies may enhance anti-tumor effects, particularly in cancers with limited treatment options. The review notes that some clinical trials using the CHEK1/2 inhibitor prexasertib alongside immune checkpoint therapies have already shown promising early results. “The initial results from this Phase I clinical trial support the immunomodulatory role of CHEK2 expression and even suggest CHEK2 potentiates immunosuppression.” Although more research is needed to confirm these mechanisms and improve treatment approaches, this review underscores the expanding role of DNA repair genes like CHEK2—not only in maintaining genome integrity but also in helping the immune system fight cancer. DOI - https://doi.org/10.18632/oncotarget.28740 Correspondence to - Crismita Dmello - stellacpak@outlook.com Video short - https://www.youtube.com/watch?v=C26pEBc0itk Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Is China's strategic push for chemical self-sufficiency reshaping the global petrochemical landscape? John Richardson, senior consultant at ICIS, joins The Chemical Show to share insights on how misjudged growth expectations for China, shifting demographics, and the rise of state-driven capacity expansions have led to the deepest, longest downturn in industry history. John and host Victoria Meyer examine why capacity was built around hopes for perpetual strong Chinese demand, only for real estate and demographic headwinds to alter the trajectory—creating a world of oversupply, negative margins, and mounting uncertainty. Their conversation covers the ongoing impact of trade tensions, the real drivers behind Chinese investment decisions, and why shutting down uneconomical assets is becoming a pressing necessity, especially in Europe and Asia. John and Victoria also weigh the challenges and promises of AI and data intelligence in a conservative, data-guarded sector, and offer advice for industry leaders navigating persistent market disruption. For chemical professionals, these perspectives highlight why adaptability, intelligence, and innovation will be critical in mastering both today's volatility and tomorrow's opportunities. Discover more about the following topics: How China's pivot from growth to self-sufficiency is reshaping global petrochemicals. Why chemicals face their worst business cycle ever, with Asian producers bleeding money on polyethylene. How tariffs and shifting policies create constant uncertainty for chemical companies. Why China's government-backed enterprises compete on strategy, not just cost. How data and artificial intelligence will separate industry winners from losers. “We've all assumed that polymer sciences are, you know, composites and stuff and playing with the same basic molecules, but maybe not.”  — John Richardson 00:00 Chemical Industry Insights by John 06:08 Domestic Chemical Manufacturing Expansion 08:48 Polyethylene Margins: China vs. Middle East 11:31 Tariffs and Global Business Perspectives 14:43 China's Trade Resilience Amid Challenges 20:23 Data Sharing's Impact on AI 23:50 Debating Productivity's True Impact 26:34 AI: Industrial Revolution or Renaissance? 30:49 Innovative Multi-Pane Glass Advancements 31:43 Innovative, Stronger Glass Advances  Subscribe to The Chemical Show on YouTube  ***Don't miss an episode: Subscribe to The Chemical Show on your favorite podcast player.  ***Like what you hear? Leave a rating and review. ***Want more insights? Sign up for our email list at https://www.thechemicalshow.com 

Listen to ASCO's Journal of Clinical Oncology Art of Oncology article, "A Whipple of Choice” by Dr. Carl Forsberg, who is an Assistant Professor of Strategy and History at Air Force War College. The article is followed by an interview with Forsberg and host Dr. Mikkael Sekeres. Dr Forsberg shares his experience with an uncommon cancer treated by a new therapy for which no directly relevant data were available. Transcript Narrator: A Whipple of Choice, by C. W. Forsberg, PDH I sat across from a hepatobiliary surgeon on a gray October afternoon. “To be frank,” he told me, “we don't know what to recommend in your case. So we default to being conservative. That means a Whipple surgery, even though there are no data showing it will improve your outcome.” The assessment surprised me, diverging from my expectation that doctors provide clear recommendations. Yet the surgeon's willingness to structure our conversation around the ambiguity of the case was immensely clarifying. With a few words he cut through the frustrations that had characterized previous discussions with other physicians. I grasped that with an uncommon cancer treated by a novel therapy with no directly relevant data, I faced a radical choice. My situation that afternoon was worlds away from where I was 5 months earlier, when I was diagnosed with presumed pancreatic cancer at the age of 35. An early scan was suspicious for peritoneal metastasis. The implications seemed obvious. I prepared myself for the inevitable, facing my fate stoically except in those moments when I lingered next to my young son and daughter as they drifted to sleep. Contemplating my death when they were still so vulnerable, I wept. Then the specter of death retreated. Further tests revealed no metastasis. New doctors believed the tumor was duodenal and not pancreatic. More importantly, the tumor tested as deficient mismatch repair (dMMR), predictable in a Lynch syndrome carrier like me. In the 7 years since I was treated for an earlier colon cancer, immune checkpoint inhibitor (ICI) immunotherapy had revolutionized treatment of dMMR and high microsatellite instability tumors. One oncologist walked me through a series of recent studies that showed extraordinary responses to ICI therapy in locally advanced colon and rectal tumors with these biomarkers.1-4 He expressed optimism that my cancer could have a similar response. I embarked on a 24-week course of nivolumab and ipilimumab. After 6 weeks of therapy, a computed tomography (CT) scan showed a significant reduction in tumor size. My health rebounded as the tumor receded. This miraculous escape, however, was bound by the specter of a Whipple surgery, vaguely promised 6 months into my treatment. At the internationally renowned center where I was diagnosed and began treatment with astonishing efficiency, neither oncologists nor surgeons entertained the possibility of a surgery-sparing approach. “In a young, healthy patient like you we would absolutely recommend a Whipple,” my first oncologist told me. A second oncologist repeated that assessment. When asked if immunotherapy could provide a definitive cure, he replied that “if the tumor disappeared we could have that conversation.” My charismatic surgeon exuded confidence that I would sail through the procedure: “You are in excellent health and fitness—it will be a delicious surgery for me.” Momentum carried me forward in the belief that surgery was out of my hands. Four months into treatment, I was jolted into the realization that a Whipple was a choice. I transferred my infusions to a cancer center nearer my home, where I saw a third oncologist, who was nearly my age. On a sunny afternoon, 2 months into our relationship, he suggested I think about a watch-and-wait approach that continued ICI therapy with the aim of avoiding surgery. “Is that an option?” I asked, taken aback. “This is a life-changing surgery,” he responded. “You should consider it.” He arranged a meeting for me with his colleague, the hepatobiliary surgeon who clarified that “there are no data showing that surgery will improve your outcome.” How should patients and physicians make decisions in the absence of data? My previous experience with cancer offered little help. When I was diagnosed with colon cancer at the age of 28, doctors made clear recommendations based on clear evidence. I marched through surgery and never second-guessed my choices. A watch-and-wait approach made sense to me based on theory and extrapolation. Could duodenal tumors treated by ICIs behave that differently from colorectal cancers, for which data existed to make a watch-and-wait approach appear reasonable? The hepatobiliary surgeon at the regional cancer center told me, “I could make a theoretical argument either way and leave you walking out of here convinced. But we simply don't know.” His comment reflects modern medicine's strict empiricism, but it foreclosed further discussion of the scientific questions involved and pushed the decision into the realm of personal values. Facing this dilemma, my family situation drove me toward surgery despite my intuition that immunotherapy could provide a definitive cure. The night before I scheduled my Whipple procedure, I wrote in my journal that “in the face of radical uncertainty one must resort to basic values—and my priority is to survive for my children. A maimed, weakened father is without doubt better than no father at all.” To be sure, these last lines were written with some bravado. Only after the surgery did I viscerally grasp that the Whipple was a permanent maiming of the GI system. My doubts lingered after I scheduled surgery, and I had a final conversation with the young oncologist at the cancer center near my home. We discussed a watch-and-wait approach. A small mass remained on CT scans, but that was common even when tumors achieved a pathological complete response.5 Another positron emission tomography scan could provide more information but could not rule out the persistence of lingering cancer cells. I expressed my low risk tolerance given my personal circumstances. We sat across from one another, two fathers with young children. My oncologist was expecting his second child in a week. He was silent for moments before responding “I would recommend surgery in your situation.” Perhaps I was projecting, but I felt the two of us were in the same situation: both wanting a watch-and-wait approach, both intuitively believing in it, but both held back by a sense of parental responsibility. My post-surgery pathology revealed a pathological complete response. CT scans and circulating tumor DNA tests in the past year have shown no evidence of disease. This is an exceptional outcome. Yet in the year since my Whipple, I have been sickened by my lack of gratitude for my good fortune, driven by a difficult recovery and a sense that my surgery had been superfluous. Following surgery, I faced complications of which I had been warned, such as a pancreatic fistula, delayed gastric emptying, and pancreatic enzyme insufficiency. There were still more problems that I did not anticipate, including, among others, stenoses of arteries and veins due to intraabdominal hematomas, persistent anemia, and the loss of 25% of my body weight. Collectively, they added up to an enduringly dysfunctional GI system and a lingering frailty. I was particularly embittered to have chosen surgery to mitigate the risk that my children would lose their father, only to find that surgery prevented me from being the robust father I once was. Of course, had I deferred surgery and seen the tumor grow inoperable or metastasize between scans, my remorse would have been incalculably deeper. But should medical decisions be based on contemplation of the most catastrophic consequences, whatever their likelihood? With hindsight, it became difficult not to re-examine the assumptions behind my decision. Too often, my dialogue with my doctors was impeded by the assumption that surgery was the obvious recommendation because I was young and healthy. The assumption that younger oncology patients necessarily warrant more radical treatment deserves reassessment. While younger patients have more years of life to lose from cancer, they also have more years to deal with the enduring medical, personal, and professional consequences of a life-changing surgery. It was not my youth that led me to choose surgery but my family situation: 10 years earlier, my youth likely would have led me to a watch-and-wait approach. The rising incidence of cancer among patients in their 20s and 30s highlights the need for a nuanced approach to this demographic.  Calculations on surgery versus a watch-and-wait approach in cases like mine, where there are no data showing that surgery improves outcomes, also require doctors and patients to account holistically for the severity of the surgery involved. Multiple surgeons discussed the immediate postsurgical risks and complications of a pancreaticoduodenectomy, but not the long-term challenges involved. When asked to compare the difficulty of my prior subtotal colectomy with that of a pancreatoduodenectomy, the surgeon who performed my procedure suggested they might be similar. The surgeon at the regional cancer center stated that the Whipple would be far more difficult. I mentally split the difference. The later assessment was right, and mine was not a particularly bad recovery compared with others I know. Having been through both procedures, I would repeat the subtotal colectomy for a theoretical oncologic benefit but would accept some calculated risk to avoid a Whipple. Most Whipple survivors do not have the privilege of asking whether their surgery was necessary. Many celebrate every anniversary of the procedure as one more year that they are alive against the odds. That I can question the need for my surgery speaks to the revolutionary transformation which immunotherapy has brought about for a small subset of patients with cancer. The long-term medical and personal consequences of surgery highlight the urgent stakes of fully understanding and harnessing the life-affirming potential of this technology. In the meantime, while the field accumulates more data, potentially thousands of patients and their physicians will face difficult decisions on surgery verses a watch and- wait approach in cases of GI tumors with particular biomarkers showing exceptional responses to ICI therapy.7,8 Under these circumstances, I hope that all patients can have effective and transparent conversations with their physicians that allow informed choices accounting for their risk tolerance, calculations of proportionality, and priorities.  Dr. Mikkael Sekeres: Hello, and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the oncology field. I'm your host, Dr. Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center at University of Miami. Today, we are so happy to be joined by Dr. Carl Forsberg, Assistant Professor of Strategy and History at the Air Force War College. In this episode, we will be discussing his Art of Oncology article, "A Whipple of Choice." At the time of this recording, our guest has no disclosures. Carl, it is such a thrill to welcome you to our podcast, and thank you for joining us. Dr. Carl Forsberg: Well, thank you, Mikkael, for having me. I'm looking forward to our conversation. Dr. Mikkael Sekeres: So am I. I wanted to start, Carl, with just a little bit of background about you. It's not often we have a historian from the Air Force College who's on this podcast. Can you tell us about yourself, where you're from, and walk us through your career? Dr. Carl Forsberg: Sure. I was born and raised in Minnesota in a suburb of Minneapolis-St. Paul and then went to undergraduate on the East Coast. I actually started my career working on the contemporary war in Afghanistan, first as an analyst at a DC think tank and then spent a year in Kabul, Afghanistan, on the staff of the four-star NATO US headquarters, where I worked on the vexing problems of Afghanistan's dysfunctional government and corruption. Needless to say, we didn't solve that problem. Dr. Mikkael Sekeres: Wow. Dr. Carl Forsberg: I returned from Afghanistan somewhat disillusioned with working in policy, so I moved into academia, did a PhD in history at the University of Texas at Austin, followed by postdoctoral fellowships at Harvard and Yale, and then started my current position here at the Air Force War College. The War Colleges are, I think, somewhat unusual, unique institutions. Essentially, we offer a 1-year master's degree in strategic studies for lieutenant colonels and colonels in the various US military services. Which is to say my students are generally in their 40s. They've had about 20 years of military experience. They're moving from the operational managerial levels of command to positions where they'll be making strategic decisions or be strategic advisors. So we teach military history, strategy, international relations, national security policy to facilitate that transition to a different level of thinking. It really is a wonderful, interesting, stimulating environment to be in and to teach in. So I've enjoyed this position here at the War College quite a lot. Dr. Mikkael Sekeres: Well, I have to tell you, as someone who's been steeped in academic medicine, it sounds absolutely fascinating and something that I wouldn't even know where to start approaching. We have postdoctoral fellowships, of course, in science as well. What do you do during a postdoctoral fellowship in history and strategy? Dr. Carl Forsberg: It's often, especially as a historian, it's an opportunity to take your dissertation and expand it into a book manuscript. So you have a lot of flexibility, which is great. And, of course, a collegial environment with others working in similar fields. There are probably some similarities to a postdoc in medicine in terms of having working groups and conferences and discussing works in progress. So it was a great experience for me. My second postdoc occurred during the pandemic, so it turned out to be an online postdoc, a somewhat disappointing experience, but nevertheless I got a lot out of the connections and relationships I formed during those two different fellowships. Dr. Mikkael Sekeres: Well, there are some people who used the pandemic as an excuse to really just plow into their writing and get immersed in it. I certainly wrote one book during the pandemic because I thought, “Why not? I'm home. It's something where I can use my brain and expand my knowledge base.” So I imagine it must have been somewhat similar for you as you're thinking about expanding your thesis and going down different research avenues. Dr. Carl Forsberg: I think I was less productive than I might have hoped. Part of it was we had a 2-year-old child at home, so my wife and I trying to, you know, both work remotely with a child without having childcare really for much of that year given the childcare options fell through. And it was perhaps less productive than I would have aspired for it to be. Dr. Mikkael Sekeres: It's terrifically challenging having young children at home during the pandemic and also trying to work remotely with them at home. I'm curious, you are a writer, it's part of your career, and I'm curious about your writing process. What triggers you to write a story like you did, and how does it differ from some of your academic writing? Dr. Carl Forsberg: Yeah. Well, as you say, there is a real difference between writing history as an academic and writing this particular piece. For me, for writing history, my day job, if you will, it's a somewhat slow, painstaking process. There's a considerable amount of reading and archival work that go into history. I'm certainly very tied to my sources and documents. So, you know, trying to get that precision, making sure you've captured a huge range of archival resources. The real narrative of events is a slow process. I also have a bad habit of writing twice as much as I have room for. So my process entailed a lot of extensive revisions and rewriting, both to kind of shorten, to make sure there is a compelling narrative, and get rid of the chaff. But also, I think that process of revision for me is where I often draw some of the bigger, more interesting conclusions in my work once I've kind of laid out that basis of the actual history. Certainly, writing this article, this medical humanities article, was a very different experience for me. I've never written something about myself for publication. And, of course, it was really driven by my own experiences of going through this cancer journey and recovering from Whipple surgery as well. The article was born during my recovery, about 4 months after my Whipple procedure. It was a difficult time. Obviously kind of in a bad place physically and, in my case, somewhat mentally, including the effects of bad anemia, which developed after the surgery. I found it wasn't really conducive to writing history, so I set that aside for a while. But I also found myself just fixating on this question of had I chosen a superfluous Whipple surgery. I think to some extent, humans can endure almost any suffering with a sense of purpose, but when there's a perceived pointlessness to the suffering, it makes it much harder. So for me, writing this article really was an exercise, almost a therapeutic one, in thinking through the decisions that led me to my surgery, addressing my own fixation on this question of had I made a mistake in choosing to have surgery and working through that process in a systematic way was very helpful for me. But it also, I think, gave me- I undertook this with some sense of perhaps my experience could be worthwhile and helpful for others who would find themselves in a situation like mine. So I did write it with an eye towards what would I like to have read? What would I like to have had as perspective from another patient as I grappled with the decision that I talk about in the article of getting a Whipple surgery. Dr. Mikkael Sekeres: So I wonder if I could back up a little bit. You talk about the difficulty of undergoing a Whipple procedure and of recovery afterwards, a process that took months. And this may come across as a really naive question, but as, you know, as an oncologist, my specialty is leukemia, so I'm not referring people for major surgeries, but I am referring them for major chemotherapy and sometimes to undergo a bone marrow transplant. Can you educate us what makes it so hard? Why was it so hard getting a Whipple procedure, and what was hard about the recovery? Dr. Carl Forsberg: Yeah, it was a long process. Initially, it was a 14-day stay in the hospital. I had a leaking pancreas, which my understanding is more common actually with young, healthy patients just because the pancreas is softer and more tender. So just, you know, vast amount of pancreatic fluid collecting in the abdominal cavity, which is never a pleasant experience. I had a surgical drain for 50-something days, spent 2 weeks in the hospital. Simply eating is a huge challenge after Whipple surgery. I had delayed gastric emptying for a while afterwards. You can only eat very small meals. Even small meals would give me considerable stomach pain. I ended up losing 40 lb of weight in 6 weeks after my surgery. Interestingly enough, I think I went into the surgery in about the best shape I had been in in the last decade. My surgeon told me one of the best predictors for outcomes is actual muscle mass and told me to work out for 2 hours every day leading up to my surgery, which was great because I could tell my wife, "Sorry, I'm going to be late for dinner tonight. I might die on the operating table." You can't really argue with that justification. So I went in in spectacular shape and then in 6 weeks kind of lost all of that muscle mass and all of the the strength I had built up, which just something discouraging about that. But just simply getting back to eating was an extraordinarily difficult process, kind of the process of trial and error, what worked with my system, what I could eat without getting bad stomach pains afterwards. I had an incident of C. diff, a C. diff infection just 5 weeks after the surgery, which was obviously challenging. Dr. Mikkael Sekeres: Yeah. Was it more the pain from the procedure, the time spent in the hospital, or psychologically was it harder? Dr. Carl Forsberg: In the beginning, it was certainly the physical elements of it, the difficulty eating, the weakness that comes with losing that much weight so quickly. I ended up also developing anemia starting about two or 3 months in, which I think also kind of has certain mental effects. My hemoglobin got down to eight, and we caught it somewhat belatedly. But I think after about three or 4 months, some of the challenges became more psychological. So I started to physically recover, questions about going forward, how much am I going to actually recover normal metabolism, normal gastrointestinal processes, a question of, you know, what impact would this have long-term. And then, as I mentioned as well, some of the psychological questions of, especially once I discovered I had a complete pathological response to the immunotherapy, what was the point to having this surgery? Dr. Mikkael Sekeres: And the way you explore this and revisit it in the essay is absolutely fascinating. I wanted to start at the- towards the earlier part of your essay, you write, "The surgeon's willingness to structure our conversation around the ambiguity of the case was immensely clarifying." It's fascinating. The ambiguity was clarifying to you. And the fact that you appreciated the fact that the surgeon was open to talking about this ambiguity. When do you think it's the right thing to acknowledge ambiguity in medicine, and when should we be more definitive? When do you just want someone to tell you, “Do this or do that?” Dr. Carl Forsberg: That's a great question, which I've thought about some. I think some of it is, I really appreciated the one- a couple of the oncologists who brought up the ambiguity, did it not at the beginning of the process but a few months in. You know, the first few months, you're so as a patient kind of wrapped up in trying to figure out what's going on. You want answers. And my initial instinct was, you know, I wanted surgery as fast as possible because you want to get the tumor out, obviously. And so I think bringing up the ambiguity at a certain point in the process was really helpful. I imagine that some of this has to do with the patient. I'm sure for oncologists and physicians, it's got to be a real challenge assessing what your patient wants, how much they want a clear answer versus how much they want ambiguity. I've never obviously been in the position of being a physician. As a professor, you get the interesting- you start to realize some students want you to give them answers and some students really want to discuss the ambiguities and the challenges of a case. And so I'm, I imagine it might be similar as a physician, kind of trying to read the patient. I guess in my case, the fact was that it was an extraordinarily ambiguous decision in which there wasn't data. So I think there is an element, if the data gives no clear answers, that I suppose there's sort of an ethical necessity of bringing that up with the patient. Though I know that some patients will be more receptive than others to delving into that ambiguity. Dr. Mikkael Sekeres: Well, you know, it's an opportunity for us to think holistically about our patients, and you as a patient to think holistically about your health and your family and how you make decisions. I believe that when we're in a gray zone in medicine where the data really don't help guide one decision versus the next, you then lean back towards other values that you have to help make that decision. You write beautifully about this. You say, "In the face of radical uncertainty, one must resort to basic values, and my priority is to survive for my children. A maimed, weakened father is without doubt better than no father at all." That's an incredibly deep sentiment. So, how do you think these types of decisions about treatment for cancer change over the course of our lives? You talk a lot about how you were a young father in this essay, and it was clear that that was, at least at some point, driving your decision. Dr. Carl Forsberg: Yeah, I certainly have spent a lot of time thinking about how I would have made this decision differently 10 years earlier. As I mentioned the article, it was interesting because most of my physicians, honestly, when they were discussing why surgery made sense pointed to my age. I don't think it was really my age. Actually, when I was 23, I went off to Afghanistan, took enormous risks. And to some extent, I think as a young single person in your 20s, you actually have generally a much higher risk tolerance. And I think in that same spirit, at a different, earlier, younger stage in my life, I would have probably actually been much more willing to accept that risk, which is kind of a point I try to make, is not necessarily your age that is really the deciding factor. And I think once again, if I were 70 or 60 and my children, you know, were off living their own lives, I think that also would have allowed me to take, um, greater risk and probably led me to go for a watch-and-wait approach instead. So there was a sense at which not the age, but the particular responsibilities one has in life, for me at least, figured very heavily into my medical calculus. Dr. Mikkael Sekeres: It's so interesting how you define a greater risk as watch and wait, whereas a surgeon or a medical oncologist who's making recommendations for you might have defined the greater risk to undergo major surgery. Dr. Carl Forsberg: And I thought about that some too, like why is it that I framed the watch and wait as a greater risk? Because there is a coherent case that actually the greater risk comes from surgery. I think when you're facing a life and death decision and the consequence, when you have cancer, of course, your mind goes immediately to the possibility of death, and that consequence seems so existential that I think it made watch and wait perhaps seem like the riskier course. But that might itself have been an assumption that needed more analysis. Dr. Mikkael Sekeres: Do you think that your doctor revealing that he also had young children at home helped you with this decision? Dr. Carl Forsberg: I think in some ways for a doctor it's important to kind of understand where your patient is in their own life. As a patient, it was interesting and always helpful for me to understand where my physicians were in their life, what was shaping their thinking about these questions. So I don't know if it in any way changed my decision-making, but it definitely was important for developing a relationship of trust as well with physicians that we could have that mutual exchange. I would consider one of my primary oncologists, almost something of a friend at this point. But I think it really was important to have that kind of two-way back and forth in understanding both where I was and where my physician was. Dr. Mikkael Sekeres: I like how you frame that in the sense of trust and hearing somebody who could make similar considerations to you given where he was in his family. One final question I wanted to ask you. You really elegantly at the end of this essay talk about revisiting the decision. I wonder, is it fair to revisit these types of decisions with hindsight, or do we lose sight of what loomed as being most important to us when we were making the decisions in real time? Dr. Carl Forsberg: That's a great question, one that is also, I think, inherent to my teaching. I teach military history for lieutenant colonels and colonels who very well may be required, God willing not, but may be required to make these sort of difficult decisions in the case of war. And we study with hindsight. But one thing I try to do as a professor is put them in the position of generals, presidents, who did not have the benefit of hindsight, trying to see the limits of their knowledge, use primary source documents, the actual memos, the records of meetings that were made as they grappled with uncertainty and the inherent fog of war. Because it is, of course, easy to judge these things in hindsight. So definitely, I kept reminding myself of that, that it's easy to second guess with hindsight. And so I think for me, part of this article was trying to go through, seeing where I was at the time, understanding that the decision I made, it made sense and with what I knew, it was probably the right decision, even if we can also with hindsight say, "Well, we've learned more, we have more data." A lot of historical leaders, it's easy to criticize them for decisions, but when you go put yourself in their position, see what the alternatives were, you start to realize these were really hard decisions, and I would have probably made the same disastrous mistake as they would have, you know. Let's just say the Vietnam War, we have our students work through with the original documents decisions of the Joint Chiefs in 1965. They very frequently come to the exact same conclusions as American policymakers made in 1965. It is a real risk making judgments purely on the basis of hindsight, and I think it is important to go back and really try to be authentic to what you knew at the time you made a decision. Dr. Mikkael Sekeres: What a great perspective on this from a historian. Carl Forsberg, I'd like to thank you, and all of us are grateful that you were willing to share your story with us in The Art of Oncology. Dr. Carl Forsberg: Well, thank you, and it's yeah, it's been a, it's a, I think in some ways a very interesting and fitting place to kind of end my cancer journey with the publication of this article, and it's definitely done a lot to help me work through this entire process of going through cancer. So, thank you. Dr. Mikkael Sekeres: Until next time, thank you for listening to JCO's Cancer Stories: The Art of Oncology. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all of ASCO's shows at asco.org/podcasts. Until next time, thank you so much. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Show notes:Like, share and subscribe so you never miss an episode and leave a rating or review.  Guest Bio: Dr. Carl Forsberg is a Assistant Professor of Strategy and History at the Air Force War College.

Last week I moderated the Truth in Beauty Panel, Surfactants Edition, at the 15th ICIS World Surfactants Conference, brought to you by the Independent Beauty Association. This episode features that conversation! How has misinformation impacted the surfactants sector? Disclaimer - surfactants are chemicals that are fundamental for much of what we have become accustomed to societally, from transportation to infrastructure and more. In cosmetics, they enable many of the different product formats, such as lotions and cleansing products. The panel included Dennis Abbeduto from Colonial Chemical, Claire Mcgahan from Stepan Company and Women in Chemicals, and Neil Burns, who put on the conference with ICIS. Big thank you to Colonial Chemical for sponsoring IBA to help make this conversation happen! Disclaimer, we had some recording challenges at the conference so this was a re-record - for those in attendance, worth a second listen since we covered a bit more! Interested in supporting the podcast? Please share, subscribe and write a review! If it's accessible, we also have a Patreon which you can find at patreon.com/theecowell

In 2010, the Association for Information Systems formed a special interest group () to nurture an international community of academics that study the role of digital technologies in fostering environmentally, economically and socially sustainable development. Fifteen years later, we sit down with , the current SIGGreen president, to reflect on the progress we have made. What do we know about how digital technologies help greening our planet? What efforts in empirical, theoretical, and design work is still needed? Is our role to understand the role of digital technologies or do we need to push and enact change ourselves? We conclude that environmental questions and problems are now firmly on the radar screen of our discipline but more work needs to be done for information systems academics to transform the way we think about and use digital technologies.  Episode reading list Corbett, J., & Mellouli, S. (2017). Winning the SDG Battle in Cities: How an Integrated Information Ecosystem can Contribute to the Achievement of the 2030 Sustainable Development Goals. Information Systems Journal, 27(4), 427-461. Seidel, S., Recker, J., & vom Brocke, J. (2013). Sensemaking and Sustainable Practicing: Functional Affordances of Information Systems in Green Transformations. MIS Quarterly, 37(4), 1275-1299. Hasan, H., Ghose, A., & Spedding, T. (2009). Editorial for the Special Issue on IT and Climate Change. Australasian Journal of Information Systems, 16(2), 19-21. Watson, R. T., Corbett, J., Boudreau, M.-C., & Webster, J. (2011). An Information Strategy for Environmental Sustainability. Communications of the ACM, 55(7), 28-30. Jenkin, T. A., Webster, J., & McShane, L. (2011). An Agenda for 'Green' Information Technology and Systems Research. Information and Organization, 21(1), 17-40. Watson, R. T., Boudreau, M.-C., & Chen, A. J. (2010). Information Systems and Environmentally Sustainable Development:  Energy Informatics and New Directions for the IS Community. MIS Quarterly, 34(1), 23-38. Elliot, S. (2011). Transdisciplinary Perspectives on Environmental Sustainability: A Resource Base and Framework for IT-Enabled Business Transformation. MIS Quarterly, 35(1), 197-236. Kahlen, M., Ketter, W., & van Dalen, J. (2018). Electric Vehicle Virtual Power Plant Dilemma: Grid Balancing Versus Customer Mobility. Production and Operations Management, 27(11), 2054-2070. Gholami, R., Watson, R. T., Hasan, H., Molla, A., & Bjørn-Andersen, N. (2016). Information Systems Solutions for Environmental Sustainability: How Can We Do More? Journal of the Association for Information Systems, 17(8), 521-536. Corbett, J., & El Idrissi, S. C. (2022). Persuasion, Information Technology, and the Environmental Citizen: An Empirical Study of the Persuasion Effectiveness of City Applications. Government Information Quarterly, 39(4), 101757. Degirmenci, K., & Recker, J. (2023). Breaking Bad Habits: A Field Experiment About How Routinized Work Practices Can Be Made More Eco-efficient Through IS for Sensemaking. Information & Management, 60(4), 103778. Zeiss, R., Ixmeier, A., Recker, J., & Kranz, J. (2021). Mobilising Information Systems Scholarship For a Circular Economy: Review, Synthesis, and Directions For Future Research. Information Systems Journal, 31(1), 148-183. Haudenosaunee Confederacy. (2025). Values. . The Stakeholder Alignment Collaborative. (2025). The Consortia Century: Aligning for Impact. Oxford University Press. Hovorka, D. and Corbett, J. (2012) IS Sustainability Research: A trans-disciplinary framework for a ‘grand challenge”. 33rd International Conference on Information Systems, Orlando, Florida. Hovorka, D. S., & Peter, S. (2021). Speculatively Engaging Future(s): Four Theses. MIS Quarterly, 45(1), 461-466. Gümüsay, A. A., & Reinecke, J. (2024). Imagining Desirable Futures: A Call for Prospective Theorizing with Speculative Rigour. Organization Theory, 5(1), . Kotlarsky, J., Oshri, I., & Sekulic, N. (2023). Digital Sustainability in Information Systems Research: Conceptual Foundations and Future Directions. Journal of the Association for Information Systems, 24(4), 936-952. Gray, P., Lyytinen, K., Saunders, C., Willcocks, L. P., Watson, R. T., & Zwass, V. (2006). How Shall We Manage Our Journals in the Future?  A Discussion of Richard T. Watson's Proposals at ICIS 2004. Communications of the Association for Information Systems, 18(14), 2-41. Saldanha, T. J. V., Mithas, S., Khuntia, J., Whitaker, J., & Melville, N. P. (2022). How Green Information Technology Standards and Strategies Influence Performance: Role of Environment, Cost, and Dual Focus. MIS Quarterly, 46(4), 2367-2386. Leidner, D. E., Sutanto, J., & Goutas, L. (2022). Multifarious Roles and Conflicts on an Inter-Organizational Green IS. MIS Quarterly, 46(1), 591-608. Wunderlich, P., Veit, D. J., & Sarker, S. (2019). Adoption of Sustainable Technologies: A Mixed-Methods Study of German Households. MIS Quarterly, 43(2), 673-691. Melville, N. P. (2010). Information Systems Innovation for Environmental Sustainability. MIS Quarterly, 34(1), 1-21. Edwards, P. N. (2013). A Vast Machine. MIT Press. Meadows, D. H., Meadows, D. L., Randers, J., & Behrens, W. W. (1972). The Limits to Growth: A Report for the Club of Rome's Project on the Predicament of Mankind. Universe Books. Over the Hedge. (2006). . McPhearson, T., Raymond, C. M., Gulsrud, N., Albert, C., Coles, N., Fagerholm, N., Nagatsu, M., Olafsson, A. S., Niko, S., & Vierikko, K. (2021). Radical Changes are Needed for Transformations to a Good Anthropocene. npj Urban Sustainability, 1(5), .   

Tariffs are shaking up the global chemical industry this year, creating uncertainty and shifting longstanding trade routes in unexpected ways. Victoria Meyer is joined by Joseph Chang and Al Greenwood of ICIS Chemical Business to break down the latest round of tariffs, including the dramatic 145% rate on Chinese imports and the sweeping, if temporary, 10% baseline affecting nearly every other country. They analyze how chemical markets from the US to Europe and Asia are being impacted, exploring falling product prices, disrupted supply chains, and the broader economic pressures facing manufacturers and end users alike.  With insights into policy-driven chaos, shifting sourcing strategies, and the growing ripple effects on sectors like housing and automotive, this episode highlights why strategic scenario planning, supply chain transparency, and adaptability are more critical than ever for chemical leaders.  Get ready for an in-depth look at these topics this week: Exploring the 2025 tariff policies and how they are reshaping chemical trade flows The economic ripple effects of the tariff policies Supply chain resilience and why chemical companies must map their entire supply chains Energy market dynamics: what is benefitting US chemical producers and what are the challenges Strategic planning in uncertainty and navigating the 90-day tariff pause Killer Quote: "Look at your supply chains. Which products are you getting from Vietnam? Which products are you getting from lower tariff countries? And see where is the most advantageous supplier with the tariffs, and also look at product substitution... You have to be cognizant, not just of your supplies, but also your products. Which products could be affected by influx of displaced shipments?" - Al Greenwood  Subscribe to The Chemical Show on YouTube  ***Don't miss an episode: Subscribe to The Chemical Show on your favorite podcast player.  ***Like what you hear? Leave a rating and review. ***Want more insights? Sign up for our email list at https://www.thechemicalshow.com  Sponsored by:Canadian Petrochemical Summit: https://www.cdnpetrochemcialsummit.ca Join chemical industry leaders, innovators, and experts at the Canadian Petrochemical Summit—the premier event for advancing the future of Canada's petrochemical sector. Set in the Canadian Rocky Mountains from June 17-19 this event will help you stay ahead of the curve. See you in the Rockies.

In this episode we're diving deep into the fascinating world of carbon recycling with a trailblazer who's reshaping how we think about waste and sustainability. Our guest is Dr. Jennifer Holmgren, CEO of LanzaTech—a company on a mission to transform our biggest environmental challenge into an economic opportunity. LanzaTech is pioneering a process that takes industrial emissions—the kind of harmful gases that typically contribute to climate change—and recycles them into valuable products like fuels, fabrics, and everyday consumer goods. The concept might sound like science fiction, but it's already science fact. LanzaTech's technology captures carbon emissions from sources like steel mills, refineries, and even municipal solid waste, then feeds those emissions to specially engineered microbes. These microbes act like tiny factories, converting carbon pollution into useful materials. Imagine jet fuel made from industrial waste or yoga pants created from captured carbon—it's not just possible; it's happening. In fact, at the very end of 2024, LanzaTech received a holiday gift from the federal government: a $200 million award from the Dept. of Energy. In this episode, Jennifer and I discuss the path LanzaTech took, including raising $400 million and taking 13 years prior to commercializing its first product. We also touch on her personal journey from her birth in Colombia to her taking the helm at LanzaTech. As you'll hear, this isn't just about reducing emissions; it's about completely rethinking the role of waste in our economy. LanzaTech's vision is one where carbon is no longer a liability but an asset—a resource that can be reused and recycled, over and over again. It's a powerful example of how businesses can align profitability with purpose, and it's precisely the kind of story that inspires hope in these challenging times. So, whether you're an entrepreneur, an environmentalist, or just someone curious about the future of our planet, this is a conversation you won't want to miss.  Discussed in this episode Jennifer recommends reading Quiet by Susan Cain. LanzaTech awarded up to $200 million in federal cash from the DOE LanzaTech is backed by Khosla Ventures. More about Jennifer Holmgren, PhD Dr. Jennifer Holmgren is CEO of LanzaTech. Under her guidance, LanzaTech is developing a variety of platform chemicals and fuels, including the world's first alternative jet fuel derived from industrial waste gases. Given her integral role in the development of this alternative jet fuel, she is also a Director and the Chair of the LanzaJet Board of Directors.  Prior to LanzaTech, Jennifer was VP and General Manager of the Renewable Energy and Chemicals business unit at UOP LLC, a Honeywell Company. While at UOP, she was a key driver of UOP's leadership in low carbon aviation biofuels, and under her management, UOP technology became instrumental in producing nearly all the initial fuels used by commercial airlines and the military for testing and certification of alternative aviation fuel. Jennifer is the author or co-author of 50 U.S. patents and more than 30 scientific publications, and is a member of the National Academy of Engineering. In 2003, she was the first woman awarded the Malcolm E. Pruitt Award from the Council for Chemical Research (CCR). In 2010, she was the recipient of the Leadership Award from the Civil Aviation Alternative Fuels Initiative (CAAFI). In 2015, Jennifer and her team at LanzaTech were awarded the U.S. Environmental Protection Agency Presidential Green Chemistry Award, and she was awarded the BIO Rosalind Franklin Award for Leadership in Industrial Biotechnology. Jennifer was named as #1 of the 100 most influential leaders in the Bioeconomy in 2017 and received the Global Bioenergy Leadership Award in 2018, and the 2020 William C. Holmberg Award for Lifetime Achievement in the Advanced Bioeconomy. In 2021, she received the Edison Achievement Award and the Prix Voltaire Award. In 2022, she was included in ICIS's Top 40 Power Players ranking. Jennifer also has an honorary doctorate from Delft University of Technology. Jennifer is on the Governing Council for the Bio Energy Research Institute in India. The institute was set up by the DBT (Department of Biotechnology, Indian Government) and IOC (Indian Oil Corporation).  She also sits on the Advisory Council for the Andlinger Center for Energy and the Environment at Princeton University, the National Academies' Board on Energy and Environmental Systems (BEES), the External Advisory Committee for the Advanced Energy Technologies Directorate (AET) at Argonne National Laboratory, the Advisory Council for the Pacific Northwest National Laboratory (PNNL), the Halliburton Labs Advisory Board, the Universiti Teknologi PETRONAS International Advisory Council, and the Founder Advisory for The Engine, a venture capital fund built by MIT that invests in early-stage science and engineering companies.  Jennifer holds a B.Sc. degree from Harvey Mudd College, a Ph.D. from the University of Illinois at Urbana-Champaign and an MBA from the University of Chicago.